Effect of Linguizhugan decoction on neuroinflammation and expression disorder of the amyloid β‑related transporters RAGE and LRP‑1 in a rat model of Alzheimer's disease

Hu,Qianfeng; Yu,Beibei; Chen,Qinlei; Wang,Yi; Ling,Yun; Sun,Songxian; Shi,Yinlong; Zhou,Chunxiang

doi:10.3892/mmr.2017.7983

Effect of Linguizhugan decoction on neuroinflammation and expression disorder of the amyloid β‑related transporters RAGE and LRP‑1 in a rat model of Alzheimer's disease

Authors:
- Qianfeng Hu
- Beibei Yu
- Qinlei Chen
- Yi Wang
- Yun Ling
- Songxian Sun
- Yinlong Shi
- Chunxiang Zhou
View Affiliations

Affiliations: Department of Febrile Disease, Basic Medicine College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210046, P.R. China, Department of Infectious Disease, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210000, P.R. China
Published online on: November 6, 2017 https://doi.org/10.3892/mmr.2017.7983
Pages: 827-834
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Linguizhugan decoction (LGZG), a notable prescription in Traditional Chinese Medicine, is a classical formula for the treatment of Alzheimer's disease (AD), inflammatory injury and fluid retention. The present study aimed to investigate the neuroprotective effect of LGZG on an amyloid β (Aβ)‑induced AD rat model. Sprague‑Dawley rats were administered with Aβ1‑42 to induce AD and inflammatory responses, and subsequently with LGZG (4.8, 2.4 or 1.2 g/kg), donepezil (2 mg/kg) or distilled water for 30 consecutive days. Learning and memory behaviors were evaluated via Morris water maze test. The neuronal impairment of AD rats was observed via hematoxylin‑eosin staining. The levels of pro‑inflammatory cytokines, and Aβ in the brain tissue were detected with ELISA kits. Protein expression levels of mitogen‑activated protein kinase and nuclear factor‑κB signalling were measured by western blot analysis. The expression of lipoprotein receptor‑related protein‑1 (LRP‑1) and receptor for advanced glycation endproducts (RAGE) in the brain were detected by western blot analysis, reverse transcription‑quantitative polymerase chain reaction and immunohistochemistry analysis. LGZG was demonstrated to significantly improve learning and memory ability, and ameliorate neuroinflammation in AD rats. LGZG increased the levels of LRP‑1 and decreased the levels of RAGE. Furthermore, the present results demonstrated that LGZG treatment significantly inhibited MAPK and NF‑κB signalling, and reduced the production of pro‑inflammatory cytokines and Aβ accumulation in AD rats. LGZG exhibited a potential protective effect on Aβ1‑42‑induced AD by regulating Aβ transportation, and inhibiting RAGE/MAPK and NF‑κB signalling. These results suggest that LGZG may be considered for the treatment of AD.

View Figures

View References

1	Ezra A, Rabinovich-Nikitin I, Rabinovich-Toidman P and Solomon B: Multifunctional effect of human serum albumin reduces Alzheimer's disease related pathologies in the 3xTg mouse model. J Alzheimers Dis. 50:175–188. 2016. View Article : Google Scholar : PubMed/NCBI
2	Keaney J, Walsh DM, O'Malley T, Hudson N, Crosbie DE, Loftus T, Sheehan F, McDaid J, Humphries MM, Callanan JJ, et al: Autoregulated paracellular clearance of amyloid-β across the blood-brain barrier. Sci Adv. 1:e15004722015. View Article : Google Scholar : PubMed/NCBI
3	Xi YD, Li XY, Ding J, Yu HL, Ma WW, Yuan LH, Wu J and Xiao R: Soy isoflavone alleviates Aβ1-42-induced impairment of learning and memory ability through the regulation of RAGE/LRP-1 in neuronal and vascular tissue. Curr Neurovasc Res. 10:144–156. 2013. View Article : Google Scholar : PubMed/NCBI
4	Do TM, Dodacki A, Alata W, Calon F, Nicolic S, Scherrmann JM, Farinotti R and Bourasset F: Age-dependent regulation of the Blood-brain barrier Influx/Efflux equilibrium of amyloid-β peptide in a mouse model of Alzheimer's disease (3xTg-AD). J Alzheimers Dis. 49:287–300. 2016. View Article : Google Scholar : PubMed/NCBI
5	Matsumoto K, Chiba Y, Fujihara R, Kubo H, Sakamoto H and Ueno M: Immunohistochemical analysis of transporters related to clearance of amyloid-β peptides through blood-cerebrospinal fluid barrier in human brain. Histochem Cell Biol. 144:597–611. 2015. View Article : Google Scholar : PubMed/NCBI
6	Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, et al: A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 122:1377–1392. 2012. View Article : Google Scholar : PubMed/NCBI
7	Erickson MA, Hartvigson PE, Morofuji Y, Owen JB, Butterfield DA and Banks WA: Lipopolysaccharide impairs amyloid β efflux from brain: Altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J Neuroinflammation. 9:1502012. View Article : Google Scholar : PubMed/NCBI
8	Ko SY, Ko HA, Chu KH, Shieh TM, Chi TC, Chen HI, Chang WC and Chang SS: The possible mechanism of advanced glycation end products (AGEs) for Alzheimer's disease. PLoS One. 10:e01433452015. View Article : Google Scholar : PubMed/NCBI
9	Wang X, Yu S, Hu JP, Wang CY, Wang Y, Liu HX and Liu YL: Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-kB pathway. Int J Neurosci. 124:601–608. 2014. View Article : Google Scholar : PubMed/NCBI
10	Lv C, Wang L, Liu X, Yan S, Yan SS, Wang Y and Zhang W: Multi-faced neuroprotective effects of geniposide depending on the RAGE-mediated signaling in an Alzheimer mouse model. Neuropharmacology. 89:175–184. 2015. View Article : Google Scholar : PubMed/NCBI
11	Di BB, Li HW, Li WP, Shen XH, Sun ZJ and Wu X: Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells. Mol Med Rep. 11:2601–2607. 2015. View Article : Google Scholar : PubMed/NCBI
12	Xiong MQ: Theory on Exogenous Febrile Disease. China Press of Traditional Chinese Medicine; Beijing: 2007
13	Yu B, Zhou C, Zhang J, Ling Y, Hu Q, Wang Y and Bai K: Latest study on the relationship between pathological process of inflammatory injury and the syndrome of spleen deficiency and fluid retention in Alzheimer's disease. Evid Based Complement Alternat Med. 2014:7435412014. View Article : Google Scholar : PubMed/NCBI
14	Sang F: Experimental research on the mechanism of Alzheimer's disease. J Tradit Chin Med. 6:685–687. 2011.
15	National Research Council: Guide for the Care and Use of Laboratory Animals: Eighth EditionGuide for the Care & Use of Laboratory Animals. The National Academies Press; pp. 1072–1073. 2010
16	Maurice T, Lockhart BP and Privat A: Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 706:181–193. 1996. View Article : Google Scholar : PubMed/NCBI
17	Cheng YF, Wang C, Lin HB, Li YF, Huang Y, Xu JP and Zhang HT: Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats. Psychopharmacology (Berl). 212:181–191. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kwon SH, Lee HK, Kim JA, Hong SI, Kim SY, Jo TH, Park YI, Lee CK, Kim YB, Lee SY and Jang CG: Neuroprotective effects of Eucommia ulmoides, Oliv. Bark on amyloid beta (25–35)-induced learning and memory impairments in mice. Neurosci Lett. 487:123–127. 2011. View Article : Google Scholar : PubMed/NCBI
19	Klunk WE, Jacob RF and Mason RP: Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal Biochem. 266:66–76. 1999. View Article : Google Scholar : PubMed/NCBI
20	Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M and Jucker M: Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 330:980–982. 2010. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Golden HL, Agustus JL, Nicholas JM, Schott JM, Crutch SJ, Mancini L and Warren JD: Functional neuroanatomy of spatial sound processing in Alzheimer's disease. Neurobiol Aging. 39:154–164. 2016. View Article : Google Scholar : PubMed/NCBI
23	Yu B: Study on the relationship between Alzheimer's disease and the syndrome of spleen deficiency and fluid retention based on Lingguizhugantang's intervention of Aβ-induced inflammatory injury (unpublished PhD dissertation). Nanjing University of TCM. 2015.
24	Harrington KD, Lim YY, Gould E and Maruff P: Amyloid-beta and depression in healthy older adults: A systematic review. Aust N Z J Psychiatry. 49:36–46. 2015. View Article : Google Scholar : PubMed/NCBI
25	Jeynes B and Provias J: Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res. 5:432–437. 2008. View Article : Google Scholar : PubMed/NCBI
26	Deane R, Bell RD, Sagare A and Zlokovic BV: Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets. 8:16–30. 2009. View Article : Google Scholar : PubMed/NCBI
27	Christensen DD: Higher-dose (23 mg/dayay) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease. Postgrad Med. 124:110–116. 2012. View Article : Google Scholar : PubMed/NCBI
28	Nordberg A: Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord. 20 2 Suppl 1:S12–S18. 2006. View Article : Google Scholar : PubMed/NCBI
29	Rogers SL, Farlow MR, Doody RS, Mohs R and Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 50:136–145. 1998. View Article : Google Scholar : PubMed/NCBI
30	Agboton C, Mahdavian S, Singh A, Ghazvini P, Hill A and Sweet A: Impact of nighttime donepezil administration on sleep in the older adult population: A retrospective study. Mental Health Clinician. 4:257–259. 2014. View Article : Google Scholar